Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inmune Bio, retaining the price target of $8.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy has given his Buy rating due to a combination of factors tied to INmune Bio’s progress with XPro in early Alzheimer’s disease. The company secured FDA agreement on a Phase 2b/3 registration trial that leverages a biomarker-enriched patient group, mirroring the subset from the earlier study that showed meaningful cognitive, behavioral, and p‑tau‑217 biomarker benefits consistent with XPro’s anti‑inflammatory mechanism.
The upcoming trial is structured to move seamlessly from a nine‑month Phase 2b into an 18‑month Phase 3 if the initial cognitive and biomarker endpoints are met, which could accelerate development timelines and de‑risk the program. McCarthy also factors in additional pipeline catalysts, such as regulatory progress for the company’s CORDStrom cell therapy program, which together support a favorable risk‑reward profile and justify maintaining a Buy recommendation on INMB shares.
McCarthy covers the Healthcare sector, focusing on stocks such as Co-Diagnostics, Plus Therapeutics, and Aprea Therapeutics. According to TipRanks, McCarthy has an average return of -22.0% and a 25.85% success rate on recommended stocks.